US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a strategic agreement with China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) to leverage their respective strengths in promoting the commercial operations of Pfizer’s established oncology drugs in China. The focus will be on drugs Aromasin (exemestane), Ibrance (palbociclib), Pharmorubicin (epirubicin), and Xalkori (crizotinib), which target lung cancer and breast cancer.
Enhancing Market Reach and Patient Access
The partnership, financial details of which were not disclosed, will capitalize on CR Pharma’s extensive market coverage and robust distribution network to increase the reach of these critical oncology drugs to more patient populations within China. This collaboration aims to improve access to life-saving treatments and enhance patient outcomes.
Pfizer’s Continued Investment in Oncology
Pfizer is committed to increasing its investment in the field of oncology, with a focus on high-incidence cancers such as lung cancer, breast cancer, urinary system tumors, and blood tumors. The company is dedicated to driving the development of innovative drugs and providing transformative treatment options for patients globally.-Fineline Info & Tech
